Tianjin Hemay Pharmaceutical

Small-molecule pharma (private)

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
PDE4Small molecule
Inflammatory Bowel DiseasePsoriasis
Ulcerative Colitis
Hemay007No recent activity
Phase 1
TNF-alphaSmall molecule
Inflammatory Bowel Disease
Crohn's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

May 2026Topline resultHemay005Phase 2 of mufemilast in ulcerative colitis: week-12 clinical remission 57% (60 mg) versus 13% (placebo)
Study investigators (Digestive Disease Week 2026) · Source ↗

Financial reports

No financial reports recorded.